Plain-English translation of NCT07172958 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called CAR-TA T cells—specialized immune cells that are engineered in a lab to recognize and attack cancer cells. These cells are made from your own immune cells, then grown in large numbers and infused back into your body along with special preparation chemotherapy. The goal is to help patients whose cancers have come back or stopped responding to standard treatments.
Some childhood cancers stop responding to available treatments or come back after treatment. Doctors need new options for these patients, and this medication represents a completely different approach—teaching the body's own immune system to fight the cancer rather than using traditional chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
First, you will have cells collected from your blood during an outpatient procedure. Those cells are then sent to the lab to be engineered and grown. Once the cells are ready, you will be admitted to Children's National Hospital for about a week. You'll receive preparation chemotherapy for a few days, then the engineered cells are infused into your bloodstream. After that, you'll have weekly clinic visits and blood tests for the first month to monitor how you're responding and watch for side effects.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States